Tai Xie

Dr. Tai Xie is the founder and CEO of CIMS Global. Dr. Xie has over 20 years of experience in clinical trial design, data collection, and management, statistical analysis, and reporting. In 2009, Dr. Xie acquired Shanghai Magnsoft Software Development Ltd., which developed the first Clinical EDC system in China. Since then, he serves as CEO and leads a team of developers to further enhance the EDC system into an Integrated Clinical Information Management Suite (CIMS). Dr. Xie is also the president and CEO of Brightech International, a data-focused CRO providing clinical data management, statistics, and SAS programming for pharmaceutical and biotech companies. Brightech has over 70 employees in the US and over 30 in China. Prior to Brightech and CIMS business, he held an Associate Director position of Biostatistics and Data Management at ImClone (now a part of Eli Lilly, 2 years), Assistant Director at Wyeth (acquired by Pfizer, 5 years), and Sr. Statistician at JNJ (2 years). He served three years as CEO of Biopharm Solutions, a biotech company focused on innovative drug delivery technologies. Dr. Xie is also an Adjunct Assistant Professor in the Biostatistics Department, School of Public Health at Rutger University. Dr. Xie obtained his doctoral degree in Applied Math and Statistics at the University of Arizona in 1993. He has extensive experience in clinical trial design and statistical analysis and reporting, clinical data management, EDC, eClinical, and eHealth. In recent years, Dr. Xie has been actively interacting with the regulatory authority and drug industry in China. He was invited several times by China’s CFDA to participate in authoring the guidance on EDC and by influential professional organizations (such as China Heart Congress, CHC) to deliver courses and speeches on a variety of topics. Dr. Xie is also an active researcher with a number of research papers published in distinguished journals on various topics including cancer prevention, adaptive design, survival analysis, personalized medicines, and more.